LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

Ketil André Camilio; Oystein Rekdal; Baldur Sveinbjörnsson

doi:10.4161/onci.29181

LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

Oncoimmunology. 2014 Jun 25:3:e29181. doi: 10.4161/onci.29181. eCollection 2014.

Authors

Ketil André Camilio¹, Oystein Rekdal², Baldur Sveinbjörnsson¹

Affiliations

¹ Lytix Biopharma AS; Tromsø, Norway ; Department of Medical Biology; Faculty of Health Sciences; University of Tromsø; Tromsø, Norway.
² Lytix Biopharma AS; Tromsø, Norway.

Abstract

Several cationic antimicrobial peptides demonstrate promising anticancer effects. We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective immune responses following intralesional administration of the peptide.

Keywords: B16 melanoma; DAMPs; anticancer peptides; immunogenic cell death; inflammation; intralesional treatment.

Publication types

Research Support, Non-U.S. Gov't